MX2010003884A - Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos. - Google Patents
Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.Info
- Publication number
- MX2010003884A MX2010003884A MX2010003884A MX2010003884A MX2010003884A MX 2010003884 A MX2010003884 A MX 2010003884A MX 2010003884 A MX2010003884 A MX 2010003884A MX 2010003884 A MX2010003884 A MX 2010003884A MX 2010003884 A MX2010003884 A MX 2010003884A
- Authority
- MX
- Mexico
- Prior art keywords
- abnormality
- related protein
- bone metabolism
- antibody targeting
- protein siglec
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Se provee un m?todo de detecci?n del metabolismo anormal de los huesos al usar un gen fuertemente expresado en un osteoclasto; un m?todo de determinaci?n selectiva de un compuesto que tiene un efecto terap?utico y/o preventivo sobre el metabolismo anormal de los huesos; y una composici?n farmac?utica para el tratamiento y/o prevenci?n del metabolismo anormal de los huesos; se provee un m?todo de detecci?n del metabolismo anormal de los huesos al usar la expresi?n de gen de Sigfec-15 humana como un ?ndice; una composici?n farmac?utica que contiene un anticuerpo que reconoce espec?ficamente Siglec-15 humana y tiene una actividad de inhibir la formaci?n de osteoclastos; y similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007265420 | 2007-10-11 | ||
PCT/JP2008/068287 WO2009048072A1 (ja) | 2007-10-11 | 2008-10-08 | 破骨細胞関連蛋白質Siglec-15を標的とした抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010003884A true MX2010003884A (es) | 2010-04-30 |
Family
ID=40549216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003884A MX2010003884A (es) | 2007-10-11 | 2008-10-08 | Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos. |
Country Status (25)
Country | Link |
---|---|
US (5) | US8546540B2 (es) |
EP (2) | EP2907826B1 (es) |
JP (4) | JPWO2009048072A1 (es) |
KR (2) | KR101577935B1 (es) |
CN (2) | CN108130327A (es) |
AU (2) | AU2008311698C1 (es) |
BR (1) | BRPI0818437B8 (es) |
CA (2) | CA2698326C (es) |
CY (1) | CY1116432T1 (es) |
DK (1) | DK2206727T3 (es) |
ES (2) | ES2540733T3 (es) |
HK (2) | HK1145847A1 (es) |
HR (1) | HRP20150485T1 (es) |
HU (1) | HUE025262T2 (es) |
IL (2) | IL204607A (es) |
MX (1) | MX2010003884A (es) |
NZ (1) | NZ583397A (es) |
PL (1) | PL2206727T3 (es) |
PT (1) | PT2206727E (es) |
RU (2) | RU2475499C2 (es) |
SG (2) | SG187523A1 (es) |
SI (1) | SI2206727T1 (es) |
TW (1) | TWI511740B (es) |
WO (1) | WO2009048072A1 (es) |
ZA (1) | ZA201001339B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
JP5173838B2 (ja) | 2006-02-13 | 2013-04-03 | アレシア・バイオセラピューティクス・インコーポレーテッド | 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列 |
CA2698326C (en) | 2007-10-11 | 2015-03-17 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
MX2011007342A (es) | 2009-04-09 | 2011-07-21 | Daiichi Sankyo Co Ltd | Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15. |
MX2013003828A (es) * | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos. |
US20130280260A1 (en) * | 2010-10-13 | 2013-10-24 | Tokyo Women's Medical University | Osteoclastogenesis inhibitor containing anti-vdac antibody |
CA2848074A1 (en) * | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
US20150125470A1 (en) | 2012-03-30 | 2015-05-07 | Daiichi Sankyo Company, Limited | Novel anti-siglec-15 antibody |
KR20150003170A (ko) | 2012-03-30 | 2015-01-08 | 다이이찌 산쿄 가부시키가이샤 | CDR 개변 항 Siglec-15 항체 |
CA2928851A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
EP3061818B1 (en) | 2013-09-30 | 2020-12-16 | Daiichi Sankyo Company, Limited | Anti-lps o11 antibody |
WO2015150326A1 (en) * | 2014-03-31 | 2015-10-08 | Universiteit Gent | A method of treating bone disease |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
AU2017330346A1 (en) | 2016-09-21 | 2019-02-21 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
EP4360714A3 (en) * | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
WO2018147245A1 (ja) | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗gprc5d抗体及び該抗体を含む分子 |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
WO2019004487A1 (ja) | 2017-06-30 | 2019-01-03 | 国立大学法人北海道大学 | 成長障害を生じない小児骨粗鬆症治療薬 |
SG11202000759XA (en) | 2017-07-27 | 2020-02-27 | Daiichi Sankyo Co Ltd | Anti-cd147 antibody |
CA3099900A1 (en) | 2018-05-31 | 2019-12-05 | Daiichi Sankyo Company, Limited | Anti-human tlr7 antibody |
AU2019311596A1 (en) | 2018-07-27 | 2021-01-28 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
CN111378043B (zh) * | 2020-02-19 | 2021-02-09 | 南京医科大学 | 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用 |
CN112159475B (zh) * | 2020-10-10 | 2021-04-30 | 南京凯地生物科技有限公司 | Siglec-15单克隆抗体及其应用 |
CN112625132B (zh) * | 2021-01-15 | 2022-08-02 | 沈阳荣欣生物制药科技有限公司 | 纳米抗体及其编码基因、表达载体、宿主细胞和应用 |
CN114957468A (zh) * | 2021-02-25 | 2022-08-30 | 石药集团巨石生物制药有限公司 | 一种抗Siglec15抗体及其用途 |
CN112961214B (zh) * | 2021-03-19 | 2022-08-02 | 江苏元本生物科技有限公司 | 一种靶向Siglec-15的噬菌体多肽 |
CN112979761B (zh) * | 2021-03-19 | 2021-12-10 | 江苏元本生物科技有限公司 | 一种靶向Siglec-15的噬菌体多肽 |
CN113577283A (zh) * | 2021-07-19 | 2021-11-02 | 河北医科大学第三医院 | Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用 |
CN114807052A (zh) * | 2022-06-07 | 2022-07-29 | 江苏亲科生物研究中心有限公司 | Siglec15单克隆抗体及其制备方法和用途 |
WO2024022008A1 (zh) * | 2022-07-26 | 2024-02-01 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
WO1998046644A1 (en) | 1997-04-15 | 1998-10-22 | Snow Brand Milk Products Co., Ltd. | Novel protein and process for producing the same |
JP4542704B2 (ja) | 1998-05-08 | 2010-09-15 | 富山化学工業株式会社 | 新規なスピロ化合物またはその塩、それらを含有する自己免疫疾患の予防・治療剤およびap−1阻害剤 |
MXPA03000514A (es) * | 2000-07-21 | 2003-10-06 | Bristol Myers Squibb Co | Lectinas relacionadas a inmunoglobulina con enlace a acido sialico y usos de los mismos. |
AU2002233994A1 (en) | 2000-11-08 | 2002-05-21 | Incyte Genomics, Inc. | Secreted proteins |
US7608704B2 (en) * | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
WO2002064771A1 (fr) | 2001-02-15 | 2002-08-22 | Mochida Pharmaceutical Co., Ltd. | Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active |
DK2270052T3 (en) * | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
US20050107588A1 (en) | 2001-11-13 | 2005-05-19 | Duggan Brendan M. | Receptors and membrane-associated proteins |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
MXPA04009681A (es) * | 2002-04-05 | 2005-01-11 | Amgen Inc | Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina. |
EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
JP4633491B2 (ja) * | 2004-02-12 | 2011-02-16 | 第一三共株式会社 | 破骨細胞関連タンパク質を標的とした抗体 |
US7405037B2 (en) | 2004-05-07 | 2008-07-29 | Lonza Walkersville, Inc. | Methods and tools for detecting collagen degradation |
CN101035807A (zh) * | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec-6相关疾病的诊断和治疗 |
JP4604184B2 (ja) | 2005-07-12 | 2010-12-22 | 独立行政法人産業技術総合研究所 | 新規糖鎖認識蛋白質及びその遺伝子 |
GB0521991D0 (en) * | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
JP5173838B2 (ja) | 2006-02-13 | 2013-04-03 | アレシア・バイオセラピューティクス・インコーポレーテッド | 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列 |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
CA2698326C (en) | 2007-10-11 | 2015-03-17 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
MX2011007342A (es) | 2009-04-09 | 2011-07-21 | Daiichi Sankyo Co Ltd | Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15. |
DK2585349T3 (en) | 2010-06-23 | 2015-03-23 | Creissels Technologies | Systems with transmission lines and remote-controlled vehicle without suspension |
MX2013003828A (es) | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos. |
US20150125470A1 (en) | 2012-03-30 | 2015-05-07 | Daiichi Sankyo Company, Limited | Novel anti-siglec-15 antibody |
KR20150003170A (ko) | 2012-03-30 | 2015-01-08 | 다이이찌 산쿄 가부시키가이샤 | CDR 개변 항 Siglec-15 항체 |
-
2008
- 2008-10-08 CA CA2698326A patent/CA2698326C/en active Active
- 2008-10-08 CN CN201710983720.8A patent/CN108130327A/zh active Pending
- 2008-10-08 MX MX2010003884A patent/MX2010003884A/es active IP Right Grant
- 2008-10-08 SG SG2013006002A patent/SG187523A1/en unknown
- 2008-10-08 PT PT88384276T patent/PT2206727E/pt unknown
- 2008-10-08 KR KR1020157004726A patent/KR101577935B1/ko active IP Right Grant
- 2008-10-08 HU HUE08838427A patent/HUE025262T2/en unknown
- 2008-10-08 SG SG10201605897RA patent/SG10201605897RA/en unknown
- 2008-10-08 EP EP15161779.2A patent/EP2907826B1/en active Active
- 2008-10-08 SI SI200831433T patent/SI2206727T1/sl unknown
- 2008-10-08 ES ES08838427.6T patent/ES2540733T3/es active Active
- 2008-10-08 JP JP2009537006A patent/JPWO2009048072A1/ja not_active Withdrawn
- 2008-10-08 BR BRPI0818437A patent/BRPI0818437B8/pt not_active IP Right Cessation
- 2008-10-08 NZ NZ583397A patent/NZ583397A/en not_active IP Right Cessation
- 2008-10-08 EP EP08838427.6A patent/EP2206727B1/en active Active
- 2008-10-08 CN CN200880110441.XA patent/CN101896501B/zh active Active
- 2008-10-08 RU RU2010106639/10A patent/RU2475499C2/ru active
- 2008-10-08 WO PCT/JP2008/068287 patent/WO2009048072A1/ja active Application Filing
- 2008-10-08 CA CA2875310A patent/CA2875310A1/en not_active Abandoned
- 2008-10-08 US US12/677,621 patent/US8546540B2/en active Active
- 2008-10-08 PL PL08838427T patent/PL2206727T3/pl unknown
- 2008-10-08 ES ES15161779T patent/ES2677246T3/es active Active
- 2008-10-08 AU AU2008311698A patent/AU2008311698C1/en not_active Ceased
- 2008-10-08 KR KR1020107005095A patent/KR101534884B1/ko active IP Right Grant
- 2008-10-08 DK DK08838427.6T patent/DK2206727T3/en active
- 2008-10-09 TW TW097138812A patent/TWI511740B/zh not_active IP Right Cessation
-
2010
- 2010-02-24 ZA ZA201001339A patent/ZA201001339B/xx unknown
- 2010-03-18 IL IL204607A patent/IL204607A/en active IP Right Grant
-
2011
- 2011-01-07 HK HK11100127.3A patent/HK1145847A1/xx not_active IP Right Cessation
- 2011-01-07 HK HK15109735.4A patent/HK1209135A1/xx not_active IP Right Cessation
-
2012
- 2012-02-27 AU AU2012201263A patent/AU2012201263B9/en not_active Ceased
- 2012-04-27 US US13/457,967 patent/US9090692B2/en active Active
- 2012-05-25 US US13/481,016 patent/US10723800B2/en active Active
- 2012-07-30 RU RU2012132678/10A patent/RU2012132678A/ru not_active Application Discontinuation
-
2013
- 2013-04-05 JP JP2013080007A patent/JP5845207B2/ja active Active
-
2014
- 2014-08-12 IL IL234078A patent/IL234078B/en active IP Right Grant
-
2015
- 2015-05-05 HR HRP20150485TT patent/HRP20150485T1/hr unknown
- 2015-06-30 CY CY20151100562T patent/CY1116432T1/el unknown
- 2015-08-14 US US14/826,515 patent/US9815899B2/en active Active
- 2015-11-20 JP JP2015227272A patent/JP6116652B2/ja active Active
-
2017
- 2017-03-21 JP JP2017053853A patent/JP6440759B2/ja active Active
- 2017-10-11 US US15/729,947 patent/US10308715B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010003884A (es) | Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos. | |
MY152033A (en) | Anti-siglec-15 antibody | |
BR112012021771A2 (pt) | métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2. | |
EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
IL195030A (en) | IV dpp inhibitor assemblies | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MY153198A (en) | Inhibitors of protein aggregation | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
IL206563A (en) | A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer | |
MX2009011949A (es) | Inhibidores de proteina activadora de 5-lipoxigenasa (flap). | |
PL2247602T3 (pl) | Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy | |
MX2010008726A (es) | Composiciones y metodos para influir en la recuperacion a partir de actividad fisica intensa. | |
WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
EP2286809A4 (en) | PERSONALIZED PHARMACEUTICAL COMPOSITION DESIGNED FOR REJUVENING SKIN AND CONTAINING RETINOIC ACID | |
BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
WO2011002834A3 (en) | Compositions and methods for diagnosis and treatment of type 1 diabetes | |
EP2279244A4 (en) | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | |
MX2009003658A (es) | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. | |
MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
BR112012007888A2 (pt) | "métodos de tratamento usando anticorpos anti-ldl oxidada". | |
TW200744577A (en) | Method for treating osteoarthritis | |
WO2009131366A3 (ko) | 위암 또는 대장암 진단 마커 및 치료제로서의 cdca5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |